Biomarker testing and adjuvant osimertinib use in patients with resectable EGFR-mutated stage IB-IIIA NSCLC: Physician practices, therapy choice, and barriers among US oncologists

被引：0
|
作者：
Aggarwal, Puja
Savill, Kristin M. Zimmerman
Jeune-Smith, Yolaine
Jennings-Zhang, Luke
Bone, Robert
Kelly, Ronan Joseph
Feinberg, Bruce A.
机构：
[1] Cardinal Hlth, Dublin, OH USA
[2] Baylor Univ, Med Ctr, Dallas, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20007
引用
收藏
页数：1
相关论文
共 21 条
  • [1] Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
    Tsuboi, M.
    Wu, Y-L.
    Grohe, C.
    John, T.
    Majem Tarruella, M.
    Wang, J.
    Kato, T.
    Goldman, J. W.
    Kim, S-W.
    Yu, C-J.
    Vu, H. Vinh
    Mukhametshina, G.
    Akewanlop, C.
    de Marinis, F.
    Shepherd, F. A.
    Urban, D.
    Stachowiak, M.
    Bolanos, A. L.
    Huang, X.
    Herbst, R. S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1413 - S1414
  • [2] Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
    Wu, Y-L.
    Tsuboi, M.
    Grohe, C.
    John, T.
    Tarruella, M. Majem
    Wang, J.
    Kato, T.
    Goldman, J. W.
    Kim, S-W.
    Yu, C-J.
    Vu, H. Vinh
    Mukhametshina, G.
    Akewanlop, C.
    de Marinis, F.
    Shepherd, F. A.
    Urban, D.
    Stachowiak, M.
    Bolanos, A.
    Huang, X.
    Herbst, R. S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1548 - S1549
  • [3] Osimertinib as adjuvant therapy in patients with resected EGFRm stage IB-IIIA NSCLC: updated results from ADAURA
    Grohe, C.
    Tsuboi, M.
    Wu, Y.
    John, T.
    Majem, M.
    Wang, J.
    Kato, T.
    Goldman, J.
    Kim, S.
    Yu, C.
    Vu, H.
    Mukhametshina, G.
    Akewanlop, C.
    de Marinis, F.
    Shepherd, F.
    Urban, D.
    Stachowiak, M.
    Balanos, A.
    Huang, X.
    Herbst, R.
    Kern, J.
    PNEUMOLOGIE, 2023, 77 : S17 - S17
  • [4] Long-term tolerability of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC) from ADAURA
    John, T.
    Grohe, C.
    Goldman, J.
    De Marinis, F.
    Kato, T.
    Wang, Q.
    Choi, J-H.
    Melotti, B.
    Fidler, M.
    Sainsbury, L.
    Stachowiak, M.
    Taggart, S.
    Wu, Y-L.
    Tsuboi, M.
    Herbst, R. S.
    Tarruella, M. Majem
    ANNALS OF ONCOLOGY, 2022, 33 : S1548 - S1548
  • [5] Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC).
    Herbst, Roy S.
    Tsuboi, Masahiro
    John, Tom
    Kato, Terufumi
    Majem, Margarita
    Grohe, Christian
    Wang, Jie
    Goldman, Jonathan W.
    Lu, Shun
    Su, Wu-Chou
    De Marinis, Filippo
    Shepherd, Frances A.
    Lee, Ki Hyeong
    Le, Nhieu
    Dechaphunkul, Arunee
    Kowalski, Dariusz M.
    Poole, Lynne
    Stachowiak, Marta
    Rukazenkov, Yuri
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
  • [6] Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC).
    Herbst, Roy S.
    Tsuboi, Masahiro
    John, Tom
    Kato, Terufumi
    Majem, Margarita
    Grohe, Christian
    Wang, Jie
    Goldman, Jonathan W.
    Lu, Shun
    Su, Wu-Chou
    de Marinis, Filippo
    Shepherd, Frances A.
    Lee, Ki Hyeong
    Le, Nhieu
    Dechaphunkul, Arunee
    Kowalski, Dariusz M.
    Poole, Lynne
    Stachowiak, Marta
    Rukazenkov, Yuri
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL)
  • [7] Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer
    Herbst, Roy S.
    John, Thomas
    Grohe, Christian
    Goldman, Jonathan W.
    Kato, Terufumi
    Laktionov, Konstantin
    Bonanno, Laura
    Tiseo, Marcello
    Majem, Margarita
    Domine, Manuel
    Ahn, Myung-Ju
    Kowalski, Dariusz M.
    Perol, Maurice
    Sriuranpong, Virote
    Ozguroglu, Mustafa
    Bhetariya, Preetida
    Markovets, Aleksandra
    Rukazenkov, Yuri
    Muldoon, Caitlin
    Robichaux, Jacqulyne
    Hartmaier, Ryan
    Tsuboi, Masahiro
    Wu, Yi-Long
    NATURE MEDICINE, 2025,
  • [8] Osimertinib as adjuvant therapy in patients with stage IB-IIIA EGFR mutation-positive (EGFRm) NSCLC after complete tumour resection: ADAURA
    John, Thomas
    Herbst, Roy
    Tsuboi, Masahiro
    Grohe, Christian
    Majem, Margarita
    Goldman, Jonathan W.
    Kim, Sang-We
    Marmol, Dominika
    Rukazenkov, Yuri
    Wu, Yi-Long
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 69 - 70
  • [9] Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA
    Grohe, C.
    Herbst, R. S.
    Tsuboi, M.
    John, T.
    Majem, M.
    Goldman, J. W.
    Kim, S. -W.
    Marmol, D.
    Rukazenkov, Y.
    Wu, Y. -L.
    Engel-Riedel, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 138 - 138
  • [10] Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
    Chen, Ping
    Yang, Qing
    Li, Yinfeng
    Jing, Xiaomei
    Chen, Jing
    FRONTIERS IN ONCOLOGY, 2022, 12
123